Marotta James C, Patel Gopesh, Carvalho Maria, Blakeney Samantha
Marotta Plastic Surgery Specialists, Smithtown, New York.
VLS Pharmacy & New Drug Loft, New York, New York.
Int J Pharm Compd. 2020 Jan-Feb;24(1):69-76.
Androgenetic alopecia is the most common form of hair loss. This condition affects both men and women causing significant psychological distress and a decrease in the quality of life. The objective of this study was to investigate the clinical efficacy and patient satisfaction of a topical compounded formulation (minoxidil 10%, finasteride 0.1%, biotin 0.2%, and caffeine citrate 0.05% hydroalcoholic solution) in male androgenetic alopecia patients. A total of five individual, prospective case studies were conducted in the private hair transplant practice of Dr. James C. Marotta. Patients were provided with the topical formulation and instructed to apply a measured 1-mL dose to the entire frontal, parietal, and occipital scalp, twice daily for 6 months. Patients visited the practice periodically (90 days, 120 days, and 180 days post-treatment) for clinical evaluation, photographic assessment, and measurement of their treatment satisfaction by the Men's Hair Growth Questionnaire. By the end of the study, at 180 days, the dermatologist-in-charge concluded that the topical treatment was successful for all five patients. Although moderate, the clinical improvements were visually noticeable as most patients had thicker, more voluminous hair; improved scalp coverage; and improved general hair appearance. These results were consistent with the photographic assessment, which demonstrated a global average increase of +1.05 in the patients' hair density. According to the patients' self-assessment, the topical compounded formulation was effective following 3 months and 6 months of continuous treatment. At 120 days, the patients' satisfaction was neutral or negative, which was likely due to negligible differences in the patients' hair growth and appearance in 90 days compared to 120 days. The results from this study suggest that the new hair-loss topical solution may be considered a safe and effective treatment option in male AGA patients.
雄激素性脱发是最常见的脱发形式。这种情况影响男性和女性，会导致严重的心理困扰和生活质量下降。本研究的目的是调查一种局部复方制剂（10%米诺地尔、0.1%非那雄胺、0.2%生物素和0.05%柠檬酸咖啡因水醇溶液）对男性雄激素性脱发患者的临床疗效和患者满意度。在詹姆斯·C·马罗塔医生的私人毛发移植诊所共进行了五项个体前瞻性病例研究。为患者提供局部制剂，并指示他们将1毫升规定剂量涂抹于整个额部、顶部和枕部头皮，每天两次，持续6个月。患者定期（治疗后90天、120天和180天）到诊所进行临床评估、照片评估，并通过男性头发生长问卷测量他们的治疗满意度。到研究结束时，即180天时，主治皮肤科医生得出结论，局部治疗对所有五名患者均成功。虽然改善程度中等，但临床改善在视觉上很明显，因为大多数患者的头发更浓密、更茂盛；头皮覆盖改善；整体头发外观改善。这些结果与照片评估一致，照片评估显示患者的头发密度总体平均增加了+1.05。根据患者的自我评估，局部复方制剂在连续治疗3个月和6个月后有效。在120天时，患者的满意度为中性或负面，这可能是由于与90天相比，120天时患者的头发生长和外观差异可忽略不计。本研究结果表明，这种新的脱发局部溶液可能被认为是男性雄激素性脱发患者的一种安全有效的治疗选择。
